Next-generation cancer immunotherapies:

Boosting T cell influx and activity in solid tumors

Oncurious focuses on the development of innovative oncology treatments designed to enhance T cell migration, infiltration and activity into resistant tumor sites. T cells are immune cells that play a key role in fighting cancer.

These next-generation cancer therapies aim to overcome tumor resistance mechanisms that current immune checkpoint inhibitors cannot address. Oncurious’ mission is to develop therapies that treat previously uncurable cancer patients by enhancing the migration of T cells into the tumor and increasing their activity.

"Immunotherapy of cancer is one of the major breakthroughs in cancer treatment over the past years, but still functions suboptimal. One of the main reasons is the immune-suppressing nature of tumors, of which regulatory T cells are important constituents. The presence of regulatory T cells in the tumor is critical to support its growth, so targeting these suppressive cells represents a very interesting therapeutic modality."

Professor Jo Van Ginderachter (VIB-VUB)

Oncurious is developing a proprietary pipeline of next-gen cancer immunotherapies modulating the tumor microenvironment to enhance T cell influx and/or activity. These therapies will complement the current clinical immuno-oncology treatment paradigms and will expand the number of cancer patients that can be treated. This includes patients with immune-excluded tumors, which are characterized by a lack of immune cells inside of the tumor. The development of these novel therapeutic territories is made possible through collaborations with world-class immuno-oncology experts in T cell and endothelial cell biology at VIB.